**Efficacy of docetaxel combined carboplatin for the treatment of patients with castration-resistant prostate cancer**

A protocol of systematic review and meta-analysis

Chun-Lin Pu, MM\textsuperscript{a,b}, Jiu-Zhi Li, MD\textsuperscript{a}, Wen-Long Fan, MB\textsuperscript{a,*} \textsuperscript{c}®

**Abstract**

**Background:** A numerous published studies have reported that docetaxel combined carboplatin (DC) has been utilized for the treatment of patients with castration-resistant prostate cancer (CRPC). However, there are still contradictory results. Therefore, this systematic review and meta-analysis will explore the efficacy and safety of DC for the treatment of patients with CRPC.

**Methods:** We will systematically and comprehensively search MEDLINE, EMBASE, Cochrane Library, Web of Science, CINAHL, WANGFANG, CBM, and CNKI from the beginning up to the March 1, 2020, regardless language and publication time. We will consider randomized controlled trials that evaluated the efficacy and safety of DC for the treatment of patients with CRPC. The treatment effects of all dichotomous data will be estimated as risk ratio and 95% confidence intervals (CIs), and that of continuous outcomes will be calculated as standardized mean difference or mean difference and 95% CIs. Methodological quality will be appraised by Cochrane risk of bias tool, and quality of evidence will be identified by Grading of Recommendations Assessment Development and Evaluation. Statistical analysis will be undertaken by RevMan 5.3 software.

**Results:** This study will systematically explore the efficacy and safety of DC for the treatment of patients with CRPC.

**Systematic review registration:** INPLASY202040076.

**Abbreviations:** CIs = confidence intervals, CRPC = castration-resistant prostate cancer, DC = docetaxel combined carboplatin, PSA = prostate-specific antigen, RCTs = randomized controlled trials.

**Keywords:** carboplatin, castration-resistant prostate cancer, docetaxel, efficacy, safety

---

1. Introduction

Castrate-resistant prostate cancer (CRPC) is progressive prostate cancer (PC) metastases in men.\textsuperscript{[1–5]} It is characterized by a continuous rise in serum prostate-specific antigen levels.\textsuperscript{[6–10]} It has been estimated that about 165,000 new PC cases, and 30,000 patients will die from PC.\textsuperscript{[11,12]} Despite most patients with PC are cured, 20% of them may experience recurrence of this disease.\textsuperscript{[13]} Although androgen deprivation therapy is utilized for the treatment of patients with recurrent, progressive, or metastatic PC, most of them will eventually develop CRPC.\textsuperscript{[14,15]}

A numerous studies have reported to use docetaxel combined carboplatin (DC) for the treatment of patients with CRPC.\textsuperscript{[16–21]} However, its efficacy and safety is still contrary, and no systematic review specifically has focused on this issue. Thus, this study will evaluate the efficacy and safety of DC for the treatment of patients with CRPC.

2. Methods

2.1. Study registration

This study has been funded and registered on INPLASY202040076. It has been reported follows the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol statement guidelines.\textsuperscript{[22]}

2.2. Inclusion criteria

2.2.1. Participants. We will include all male participants who were diagnosed as CRPC, in spite of their country, race, age, and duration and severity of CRPC.
2.2.2. Interventions/exposure. In the experimental group, all patients underwent DC as their treatment for CRPC. In the control group, there are no restrictions to the control treatments. However, we will exclude studies that utilized DC or any comparators involved DC.

2.2.3. Study types. All potential randomized controlled trials (RCTs) that investigated the efficacy and safety of DC for the treatment of patients with CRPC will be included. However, any other studies, such as animal studies, case studies, reviews, comments, non-clinical studies, and uncontrolled clinical studies will be excluded.

2.2.4. Outcome measurements

2.2.4.1. Primary outcome. Disease-free survival (defined as length of time after treatment during which no disease is found);

2.2.4.2. Secondary outcomes. Overall survival (defined as the time from randomization to death by any reasons);

Progression-free survival (defined as the time from randomization to disease progression or death by any reasons);

Prostate-specific antigen (PSA) response rate;

Duration of PSA response;

Quality of life (as measured by any relevant scales reported in the trials); and adverse events.

2.3. Literature search

This review will systematically and comprehensively retrieve all potential RCTs in MEDLINE, EMBASE, Cochrane Library, Web of Science, CINAHL, WANGFANG, CBM, and CNKI from the beginning up to the March 1, 2020, regardless language and publication time. All related RCTs that assessed the efficacy and safety of DC for the treatment of patients with CRPC will be considered for inclusion. We have created search strategy sample for MEDLINE in Table 1, and will adapt similar search strategies for other electronic databases.

In addition, we will seek other resources for more potential studies, such as dissertations and reference lists of associated reviews.

2.4. Study selection

Two members of our study team will independently scan the titles/abstracts of all searched citations according to the previously designed eligibility criteria. Literatures that are irrelevant to study topic will be excluded. Full papers of all remaining studies will be further read to judge if they fulfill all inclusion criteria. Any disagreements will be solved by discussion with a third team member. The procedure of study selection is demonstrated in a flow chart.

2.5. Data extraction and management

Two team members will extract data using a pre-designed data extraction sheet. It comprises of the following information: publication information (such as first author, time of publication), patient characteristics (such as race, age, eligibility criteria, duration, and severity of CRPC), study design (such as sample size, randomization details), details of treatment and comparators, outcome indicators, safety, follow-up data, and conflict of interest. Any differences between 2 members will be solved by consulting a third member and a consensus will be reached after discussion. If insufficient or missing data is examined, we will contact primary authors to request it.

2.6. Study quality assessment

Two team members will independently assess methodological quality by Cochrane Collaboration’s tool. We will appraise study quality for each eligible trial through seven aspects and each one is graded as low, unclear or high risk of bias. Any different views between two members will be settled by a third member through a consensus meeting.

2.7. Measurement of treatment effect

We will estimate the pooled treatment effects for continuous data as mean difference or standardized mean difference and 95% confidence intervals (CIs), and dichotomous data as risk ratio and 95% CIs.

2.8. Assessment of heterogeneity

We will employ $I^2$ test to examine statistical heterogeneity among included trials. We define $I^2 \leq 50\%$ as homogeneity, and $I^2 > 50\%$ as obvious heterogeneity.

2.9. Data synthesis

We will apply RevMan 5.3 software to analyze outcome data and perform a meta-analysis. If homogeneity is found, a fixed-effects model will be used for data pooling, and a meta-analysis will be carried out if sufficient data is extracted. On the other hand, if considerable heterogeneity is examined, a random-effects model will be utilized for data synthesis, and a subgroup analysis will be performed to test the sources of remarkable heterogeneity. If we can still identify obvious heterogeneity after subgroup analysis, we will not consider conducting a meta-analysis.
2.10. Subgroup analysis
We will carry out a subgroup analysis to figure out sources of obvious heterogeneity across studies according to the different types of treatments, controls, and outcomes.

2.11. Sensitivity analysis
We will conduct a sensitivity analysis to test the robustness of study findings by removing studies with high risk of bias.

2.12. Reporting bias
We will undertake a funnel plot and Egger regression test to identify any possible reporting biases if at least 10 RCTs are included.[23]

2.13. Dissemination and ethics
We will submit this study on an academic journal or a conference meeting. This study will not collect privacy data, since no ethical approval is required.

3. Discussion
CRPC is a very tricky type of PC. Although a variety of previous studies have found that DC can be used to treat CRPC, their results are still inconsistent.[16-21] The purpose of this study is to summarize the most recent evidence of DC in the treatment of CRPC. To avoid potential bias, we will collect all relevant records as comprehensive as possible. As to exploration the potential obvious heterogeneity, we will carry out subgroup analysis. The findings of this study will help to determine whether DC is effective and safety for the treatment of patients with CRPC.

Author contributions
Conceptualization: Chun-Lin Pu, Jiu-Zhi Li, Wen-Long Fan.
Data curation: Wen-Long Fan.
Formal analysis: Chun-Lin Pu.
Funding acquisition: Wen-Long Fan.
Investigation: Wen-Long Fan.
Methodology: Chun-Lin Pu, Jiu-Zhi Li.
Project administration: Wen-Long Fan.
Resources: Chun-Lin Pu, Jiu-Zhi Li.
Software: Chun-Lin Pu, Jiu-Zhi Li.
Supervision: Wen-Long Fan.
Validation: Chun-Lin Pu, Jiu-Zhi Li, Wen-Long Fan.
Visualization: Chun-Lin Pu, Wen-Long Fan.
Writing – original draft: Chun-Lin Pu, Jiu-Zhi Li, Wen-Long Fan.
Writing – review & editing: Chun-Lin Pu, Jiu-Zhi Li, Wen-Long Fan.

References
[1] Tucci M, Zichi C, Buttigliero C, et al. Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. Onco Targets Ther 2018;11:7353-68.
[2] Gong P, Liu H, Liu X, et al. Efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2018;97:e13204.
[3] Mateo J, Fizazi K, Gillessen S, et al. Managing nonmetastatic castration-resistant prostate cancer. Eur Urol 2019;75:285-93.
[4] Wang K, Ruan H, Xu T, et al. Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer. Onco Targets Ther 2018;11:3367-78.
[5] Luo J, Beer TM, Graff JN. Treatment of nonmetastatic castration-resistant prostate cancer. Oncology (Williston Park) 2016;30:336-44.
[6] Gkisakis I, Fragkoudis C. Emerging therapies targeting castration-resistant prostate cancer. J BUON 2015;20:1389-96.
[7] Chandrasekhar T, Yang JC, Gao AC, et al. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol 2015;4:365-80.
[8] Scher HI, Solo K, Valant J, et al. Prevalence of prostate cancer clinical trials registry report. JAMA 2007;298:2100-6.
[9] Lian F, Sharma NV, Moran JD, et al. The biology of castration-resistant prostate cancer. Curr Probl Cancer 2015;39:17–28.
[10] Suzman DL, Antonarakis ES. Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol 2011;4:167–79.
[11] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30.
[12] Scher HI, Solo K, Valant J, et al. Prevalence of prostate cancer clinical trials report. JAMA 2007;298:2100-6.
[13] Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65:1180–92.
[14] Nguyen PL, Alhbeta SM, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015;67:825–36.
[15] Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25:1596–605.
[16] Bouman-Wammes EW, van den Berg HP, de Munck L, et al. Carboplatin plus docetaxel plus cabazitaxel in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: the RECADO trial. Eur J Cancer 2018;90:1–9.
[17] Vaishampayan U, Shevrim D, Stein M, et al. Phase II trial of carboplatin, etoposide, and prednisone in metastatic castration-resistant prostate cancer pretreated with docetaxel chemotherapy: a prostate cancer clinical trial consortium study. Urolgy 2015;86:1206–11.
[18] Narita S, Tsuchiya N, Yuasa T, et al. Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and cabazitaxel for castration-resistant prostate cancer. Int J Clin Oncol 2012;17:204–11.
[19] Reuter CW, Morgan MA, Ivzini P, et al. Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer. World J Urol 2010;28:391–8.
[20] Sella A, Yarom N, Zisman A, et al. Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer. Oncology 2009;76:442–6.
[21] Loriot Y, Massard C, Gross-Goupil M, et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol 2009;20:703–8.
[22] Shamsaei I, Moher D, Clarke M, et al. PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.
[23] Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005;58:882–93.